biontech mrna - Search News

News

BioNTech to buy German rival CureVac for $1.25B

MedCity News · 2d

BioNTech to Buy CureVac in $1.25B Stock Deal That Would Also End mRNA Patent Dispute

BioNTech is acquiring CureVac in a deal that brings messenger RNA manufacturing capability and cancer immunotherapy candidates. Analysts say the M&A deal is a way to essentially settle out of court the ongoing mRNA patent dispute between the companies following some recent CureVac legal wins.

Reuters on MSN · 2d

BioNTech takes over CureVac in $1.25 billion all-stock deal among COVID rivals

By Ludwig Burger (Reuters) -German biotech firm BioNTech has agreed to acquire domestic peer CureVac for about $1.25 billion worth of BioNTech shares, it said on Thursday, to boost its work on new mRNA-based cancer treatments.

PharmTech · 1d

CureVac to Be Acquired by BioNTech in $1.25B Deal to Advance mRNA Cancer Therapies

The acquisition boosts BioNTech’s mRNA design and manufacturing capabilities, accelerating development of next-gen cancer immunotherapies.

GlobalData on MSN2d

BioNTech bolsters mRNA pipeline with $1.25bn CureVac acquisition

BioNTech has agreed to acquire mRNA specialist CureVac for approximately $1.25bn, as the big pharma company amps up its ...

BioNTech expands mRNA capabilities with $1.25bn CureVac acquisition

BioNTech has announced that it will be expanding its messenger RNA (mRNA) capabilities by acquiring CureVac for approximately ...

BioNTech to buy fellow German mRNA firm CureVac

The German mRNA firm BioNTech has announced that it will buy local rival CureVac in an all-stock transaction that values ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results